Furthermore, NF-κB inhibition by administration of Withaferin A, a known NF-κB inhibitor, reduced ALS disease symptoms in a TDP-43 transgenic mouse model [14] and extended lifespan of mutant SOD1 ALS mice [15]. Here, TARDBP is linked to amyotrophic lateral sclerosis.